BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SanBio, Inc. Announces The First Public Presentation Of Data From Its On-Going Human Clinical Trial Of Cell Therapy For Chronic Stroke Disability


2/14/2014 9:44:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MOUNTAIN VIEW, Calif.
, Feb. 14, 2014 /PRNewswire/ -- SanBio today announced the presentation of safety and efficacy data from its on-going Phase 1/2a clinical trial of SB623 cell therapy in patients with chronic stroke disability. The presentation was made by Dr. Gary Steinberg, M.D., Ph.D., Bernard and Ronni Lacroute-William Randolph Hearst Professor of Neurosurgery and the Neurosciences, Chairman, Department of Neurosurgery, Stanford University School of Medicine, at a scientific session on Thursday at the International Stroke Conference in San Diego, CA. Dr. Steinberg is the Principal Investigator for this study at Stanford.

The data presented show that the clinical outcome results showing benefit on all three stroke scales (NIHSS, ESS and Fugl-Meyer) were highly significant at 6, 9 and 12 months post treatment. There have been no serious adverse events attributable to the cell therapy product.

This open-label clinical trial tests the safety and efficacy of a cell therapy product, SB623, in patients suffering from fixed motor deficits resulting from a subcortical ischemic stroke. The 18 patients range from 7 to 36 months post-stroke. SB623 was administered to the region adjacent to the damaged part of the brain.

"We are extremely pleased that this human clinical trial is going well. We look forward to taking it to the next phase trial for the many stroke patients in need," said Keita Mori, SanBio CEO.

"This study represents the first step in a novel therapeutic approach for the treatment of otherwise permanently impaired stroke patients. I am encouraged by the results thus far and am enthusiastic to initiate the next study," said Dr. Gary Steinberg, Principal Investigator.

A full description of the experimental results will be published later this year.

About SB623: SB623 is a proprietary allogeneic cell therapy product consisting of cells derived from bone marrow. SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: www.san-bio.com

SOURCE SanBio Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES